January 9, 2026

Webinar: Public Health and Regulatory Considerations for Kratom and 7 -OH Products, January 30
This session is designed to clarify the distinctions between natural kratom leaf (which contains trace amounts of 7-OH) and the newer potent products with added or synthetic 7-OH that are increasingly available in retail settings and online. The webinar will address the growing concerns among health care professionals, public health officials, and community advocates regarding the misuse, unpredictable potency, and emerging health risks associated with these unregulated substances and current legislative efforts.
Key Topics
- Pharmacology and Health Effects:
- Discuss how kratom’s primary compounds, mitragynine and 7-OH, interact with the body’s opioid receptors and the potential for both stimulant and potent opioid-like effects.
- Public Health Concerns:
- Review data on adverse effects, including addiction potential, neonatal opioid withdrawal syndrome, overdose risks (especially when combined with other substances like alcohol or benzodiazepines) and contamination issues.
- Regulatory Landscape:
- Examine the complex and patchwork regulatory status at federal and state levels, including the FDA’s position that kratom is an unapproved new dietary ingredient and cannot be lawfully marketed as such.
- Recent Agency Actions:
- Outline recent actions by the FDA and state authorities, such as FDA warning letters to companies illegally marketing 7-OH products and the FDA’s recommendation to the DEA to classify concentrated 7-OH as a controlled substance.
Cost: Complimentary for all attendees
When: Friday, January 30, 11:00 a.m. – 12:00 p.m.
Click Here to Register


